Paul Shannon, MD
Urology · Huntington, NYNPI 1851562342
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Astellas Pharma US Inc at 34.6% of the total. Reporting peaked in 2019 at $1,153 and has fallen 68.8% since, to $360 in 2025.
Across 209 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$1K
- Sumitomo Pharma America, Inc.$427
- Urovant Sciences Inc$320
- Bayer$305
- AbbVie$219
- Boston Scientific$191
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,92094%
- Education$2436%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 59 | $1,440 |
| Sumitomo Pharma America, Inc. | 35 | $427 |
| Urovant Sciences Inc | 15 | $320 |
| Bayer | 17 | $305 |
| AbbVie(2 entities) | 13 | $219 |
| Boston Scientific | 8 | $191 |
| Endo Pharmaceuticals Inc. | 9 | $180 |
| Pfizer | 10 | $159 |
| Tolmar, Inc. | 3 | $79 |
| Tolmar Pharmaceuticals, Inc. | 4 | $74 |
| Johnson & Johnson | 4 | $72 |
| Novartis | 4 | $70 |
| Urogen Pharma, Inc. | 3 | $70 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $59 |
| Ferring Pharmaceuticals Inc. | 3 | $55 |
| Coloplast | 2 | $50 |
| Procept Biorobotics Corporation | 2 | $49 |
| Blue Earth Diagnostics | 2 | $45 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Neotract Inc. | 1 | $30 |
| Progenics Pharmaceuticals, Inc. | 1 | $30 |
| Amgen | 2 | $29 |
| Hollister Incorporated | 1 | $23 |
| Acerus Pharmaceuticals Corporation | 1 | $22 |
| Vertex | 1 | $20 |
| Olympus America Inc. | 1 | $19 |
| Medtronic | 1 | $17 |
| Davol Inc. | 1 | $17 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Profound Medical Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,163 in reported general payments places this provider in the 60th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 75 | $67,898 |
| MyrbetriqMirabegron | 39 | $31,327 |
| Tamsulosin Hcl | 469 | $6,619 |
| Bethanechol Chloride | 77 | $3,251 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 13 | $2,533 |
| Finasteride | 160 | $1,804 |
| Potassium Citrate ErPotassium Citrate | 13 | $1,487 |
| Doxycycline Hyclate | 170 | $1,170 |
| Methenamine Hippurate | 13 | $1,143 |
| Silodosin | 22 | $1,103 |
| Solifenacin Succinate | 19 | $1,078 |
| Dutasteride | 38 | $1,041 |
| Betamethasone Dipropionate | 15 | $831 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 33 | $644 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 32 | $631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $427 | $67,89875 claims |
| Astellas Pharma US IncMyrbetriq | $1,440 | $31,32739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 urology providers in New York.
Other urology in Huntington
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Evan GoldfischerPoughkeepsie$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.